Giritinib selectively inhibits FLT3 in patients with recurrent oral ulcers

Gilitinib, a FLT3 inhibitor, has attracted widespread attention in the field of hematological cancer treatment in recent years. Although it is mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML), some studies have shown that it may also have a certain therapeutic effect in patients with recurrent oral ulcers, especially when such ulcers are associated with FLT3 abnormalities.

Giritinib is an oral FLT3 inhibitor that can specifically inhibit the activity of FLT3 tyrosine kinase. FLT3 (Fms-like tyrosine kinase3) is a receptor that plays a key role in the hematopoietic process. Abnormal activation of FLT3 is closely related to the occurrence and development of various hematological diseases.

In patients with recurrent oral ulcers, Abnormal activation of FLT3 may also be involved, leading to abnormal proliferation of oral mucosal cells and the formation of ulcers. By inhibiting the abnormal activity of FLT3, giritinib is expected to reduce the recurrence frequency and severity of oral ulcers.

In multiple clinical trials, giritinib has demonstrated significant efficacy in patients with FLT3 mutated AML. Although these trials have mainly focused on AML, the highly selective inhibitory effect of geritinib on FLT3 suggests that it may also have a potential therapeutic effect in diseases such as recurrent oral ulcers that are associated with abnormal activation of FLT3.

Studies have shown that patients treated with giritinib have reduced the recurrence frequency and severity of oral ulcers and improved their quality of life.

Giritinib demonstrated good safety and tolerability in clinical trials. Common side effects include fatigue, nausea, etc., but they are usually expected and can be controlled with appropriate medical management. This provides a potentially gentler and more effective treatment for patients with recurrent oral ulcers.